Xenon lung imaging in COPD: a COPD Cohort sub-study Version 1.0

• Research type

  Research Study

• Full title

  Hyperpolarised xenon magnetic resonance imaging (Xe-129 MRI) lung imaging in COPD

• IRAS ID

  90024

• Contact name

  Annabel H Nickol

• Sponsor organisation

  Oxford University Hospitals NHS Foundation Trust

• Eudract number

  2011-002038-37

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Hyperpolarised xenon lung magnetic resonance imaging (Xe-129 MRI) is a technique that uniquely has the ability to determine detailed lung anatomy and function simultaneously. It has enormous potential to advance understanding and treatment of chronic obstructive pulmonary disease (COPD). COPD is common (10% adults over 40) and accounts for a large number of hospital bed-days and prescriptions. Current treatments make only a small difference to symptoms and disease progression. One of the problems in improving treatment is that there are large differences in symptoms between patients, which are inadequately explained using currently available techniques. Up until now, COPD assessment tools have only been able to look separately at overall lung function or anatomy. These techniques may miss important localised changes within the lungs that determine patients?? symptoms and response to treatment. Xe-129 MRI lung imaging will enable the anatomy and function of small areas within the lung to be examined simultaneously in detail, thereby increasing the potential to understand the great variation in symptoms and functional performance between individuals, and tailor treatments accordingly. The current proposal (1) further develops technical aspects of this imaging modality in COPD, (2) tests the hypothesis that it is a better predictor of exercise ability and shortness of breath than current assessment methods, and (3) evaluates longitudinal changes in imaging that occur during disease stability and during exacerbation. Patients will be recruited from our Oxford Biomedical Research Centre COPD Registry and Cohort. As part of this Registry/ Cohort patients take part in very detailed assessments (phenotyping) and genetic analysis (genotyping), and give their consent to be contacted regarding future studies such as the current proposal. Lung imaging will extend this detailed phenotyping, and is thus a sub-study of the COPD Registry/ Cohort.

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  11/SC/0488

• Date of REC Opinion

  3 Jan 2012

• REC opinion

  Further Information Favourable Opinion